Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018

Size: px
Start display at page:

Download "Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018"

Transcription

1 Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018

2 Our Journey to Clinical Research

3 Types of Research Animal Behavioral Basic/Fundamental Translational Clinical (Human Subjects)

4 4 What is Human Subjects Research?

5 What is Human Subjects Research? Research: a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Human subject: a living individual about whom an investigator (whether professional or student) conducting research obtains (1) Data through intervention or interaction with the individual, or (2) Identifiable private information. 5

6 Human Subjects Research at Havener Eye Institute Interventional (clinical trials) Observational (clinical studies) Translational Longitudinal 6

7 Clinical Trial vs Clinical Study? Clinical Research Design No Intervention Intervention Observational Experimental Comparison Group Random Allocation Yes No Yes No Analytical study (case control, cohort) Descriptive Study Randomized Controlled Trial Non-Randomized

8 OPTHEA Clinical Trial Primary Objective To determine the efficacy of two different doses of intravitreal OPT-302 when administered in combination with Lucentis in patients with wet AMD Primary Endpoint The primary endpoint is mean change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) letters.

9 Ophthalmology Clinical Trial & Public Health Implications An example: Early Treatment Diabetic Retinopathy Study (EDTRS) Primary Question: When in the course of diabetic retinopathy is it most effective to initiate treatment, specifically photocoagulation?

10 Corneal Biomechanics in Ocular Disease Study Uses various devices to define the relationship between intraocular pressure (IOP) and corneal stiffness under an applied air pulse Recruitment cohorts Healthy eye volunteers Diabetic Primary Open Angle Glaucoma Ocular Hypertension Keratoconus Age-Matched Recruitment

11 Translational Research Applies discoveries generated in the lab or preclinical studies to the development in trials and studies in humans Basic Research Clinical Research Improved Health

12 Measurements of Corneoscleral Biomechanics Using Ultrasound Developed high-frequency ultrasound imaging device Will aid in detecting and diagnosing various corneal pathology and glaucoma

13 Ocular Hypertension Treatment Study Stage 1 (1994): Determine the safety & efficacy of topical ocular hypotension medication Stage 2 (2002): Compare safety & efficacy of earlier vs later treatment in preventing Primary Open-Angle Glaucoma (POAG) Stage 3 (2015): Determine the 20-year incidence of POAG & develop a 20-year glaucoma prediction model

14 Closing Remarks

15 15 References Glaucoma Projected to Increase Significantly Due To Aging U.S. Population. (n.d.). Retrieved April 10, 2018, from Kass MA. The ocular hypertension treatment study. J Glaucoma. 1994;3(2): Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128(3): Protecting Human Subjects. Protecting Human Subjects UCSF Institutional Review Board, 1 Jan. 1970, irb.ucsf.edu/. Royle P, Mistry H, Auguste P, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jul. (Health Technology Assessment, No ) Chapter 2, The landmark trials: Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study.Available from: Rubio, D. M., Schoenbaum, E. E., Lee, L. S., Schteingart, D. E., Marantz, P. R., Anderson, K. E., Esposito, K. (2010). Defining Translational Research: Implications for Training. Academic Medicine : Journal of the Association of American Medical Colleges, 85(3),

MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT

MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT Hussein Hollands, MD, MS (epid) Peter J. Kertes, MD, CM, FRCS(C) 72 The purpose of

More information

Dr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University.

Dr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University. Dr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University. Although the clinical picture of glaucoma is well described, the exact mechanism leading to this specific type of damage to the optic

More information

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing

More information

Present relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.

Present relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS. Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should

More information

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment

More information

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company

More information

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment

More information

Common Causes of Vision Loss

Common Causes of Vision Loss Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic

More information

Long Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up

Long Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up Long Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up Lawrence F. Jindra, MD Columbia University Winthrop University Hospital Disclosure Speaker has independently conducted and financed

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Conversion of Ocular Hypertensives into Glaucoma: A Retrospective Study Aditi Singh 1, Shibi

More information

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Pachymetry Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Pachymetry Professional Institutional Original Effective Date: March 11, 2004 Original Effective

More information

IRIDEX MicroPulse P3: innovative cyclophotocoagulation

IRIDEX MicroPulse P3: innovative cyclophotocoagulation Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:107-111 GENERAL ARTICLE IRIDEX MicroPulse P3: innovative cyclophotocoagulation Gavris M. Monica*, Olteanu Ioana*, Kantor Erzsebet*,

More information

Diabetic Learning Event: Diabetic Eye Screening and Retinopathy- Samantha Mann & Mark Frost

Diabetic Learning Event: Diabetic Eye Screening and Retinopathy- Samantha Mann & Mark Frost Diabetic Learning Event: Diabetic Eye Screening and Retinopathy- Samantha Mann & Mark Frost Case 1 : 63 yr-old Caucasian woman with type-2 Diabetes for 8 years Ex-smoker Hypertension- 5 years FH: father

More information

Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)

Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Aggiornamento biotecnologico: MoAb anti VEGF Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Giulia Germena AMD DRY (non-neovascular) Atrophic cell death in the macula No leakage WET

More information

MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND PACHYMETRY. POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND PACHYMETRY. POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND,, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Management of Neovascular AMD

Management of Neovascular AMD Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,

More information

Abbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )

Abbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert ) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Ophthalmol Ther (2015) 4:51 58 DOI 10.1007/s40123-015-0028-0 CASE REPORT Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Thomas Bertelmann

More information

2016 PQRS Recommended Measures for: Ophthalmology

2016 PQRS Recommended Measures for: Ophthalmology Measures Groups Choose 1 Measures Group Report on a minimum of 20 eligible patients (at least 11 must be Medicare Part B FFS patients) #130: Documentation of Current Medications in the Medical Record #226:

More information

Diabetic Retinopatathy

Diabetic Retinopatathy Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced

More information

DIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS

DIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS DIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS Dr. Sehnaz Karadeniz Diabetic retinopathy is one of the most feared complications of diabetes and one of the leading causes of

More information

Ocular hypertension is present in approximately 8%

Ocular hypertension is present in approximately 8% ORIGINAL STUDY The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator Steven L. Mansberger, MD, MPH and George A. Cioffi, MD Objective: To

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Ocular Hypertension Treatment Study. Manual of Procedures. Version /17/2015

Ocular Hypertension Treatment Study. Manual of Procedures. Version /17/2015 Ocular Hypertension Treatment Study Manual of Procedures Version 2.0 12/17/2015 Ocular Hypertension Treatment Study Manual of Procedures Version 2.0 12/17/2015 Summary of Changes Section 2.2 Section 2.3

More information

FROM OUTDATED TO UPDATED Eminence-Based Medicine

FROM OUTDATED TO UPDATED Eminence-Based Medicine FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS

More information

Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function?

Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function? Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function? Supported by the National Eye Institute (EY 09307, EY 09341) National Center on Minority

More information

The Era of anti- - - VEGF Kirk L. Halvorson, OD

The Era of anti- - - VEGF Kirk L. Halvorson, OD The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety

More information

measure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control

More information

Clinically Significant Macular Edema (CSME)

Clinically Significant Macular Edema (CSME) Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2

More information

Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014

Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014 Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars 2014 Declaration of interest I have sat on Advisory boards for Novartis and Bayer Involved in Novartis sponsored

More information

Clinical Trials Related to Age Related Macular Degeneration

Clinical Trials Related to Age Related Macular Degeneration Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad

More information

Opinion 4 December 2013

Opinion 4 December 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 4 December 2013 LUCENTIS 10 mg/ml, solution for injection Vial of 0.23 ml (CIP: 34009 378 101 5 9) Applicant: Novartis

More information

Vanderbilt Eye Institute Clinical Trials

Vanderbilt Eye Institute Clinical Trials April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director

More information

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors

More information

Behandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS

Behandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS Behandlungsstrategien beim Offenwinkelglaukom F. Bochmann, Augenklinik LUKS What is strategy? what is our goal? where are we? how can we achieve our goal? Mission Statement The goal of glaucoma management

More information

Vascular Disease Ocular Manifestations of Systemic Hypertension

Vascular Disease Ocular Manifestations of Systemic Hypertension Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular

More information

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.

More information

ILUVIEN IN DIABETIC MACULAR ODEMA

ILUVIEN IN DIABETIC MACULAR ODEMA 1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for

More information

CLASS-y Laser Treats Glaucoma

CLASS-y Laser Treats Glaucoma Article # 404 Comments About the Author Released: Author: Category: March 12th, 2014 Issue #0314 Ehud Assia Feature S S S S S CLASS-y Laser Treats Glaucoma Transforming complex, invasive and risky glaucoma

More information

Changes in Central Corneal Thickness over Time

Changes in Central Corneal Thickness over Time Changes in Central Corneal Thickness over Time The Ocular Hypertension Treatment Study James D. Brandt, MD, 1 Mae O. Gordon, PhD, 2 Julia A. Beiser, MS, 2 Shan C. Lin, MD, 3 Monica Y. Alexander, MD, 4

More information

Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study

Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2

More information

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO) Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital

More information

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic

More information

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular

More information

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013

More information

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RANIBIZUMAB (Lucentis Novartis Pharmaceuticals Canada Inc.) New Indication: Macular Edema Secondary to Retinal Vein Occlusion Recommendation: The Canadian Drug Expert Committee

More information

Jose M. Martinez-de-la-Casa, Julian Garcia-Feijoo, Ana Fernandez-Vidal, Carmen Mendez-Hernandez, and Julian Garcia-Sanchez METHODS

Jose M. Martinez-de-la-Casa, Julian Garcia-Feijoo, Ana Fernandez-Vidal, Carmen Mendez-Hernandez, and Julian Garcia-Sanchez METHODS Ocular Response Analyzer versus Goldmann Applanation Tonometry for Intraocular Pressure Measurements Jose M. Martinez-de-la-Casa, Julian Garcia-Feijoo, Ana Fernandez-Vidal, Carmen Mendez-Hernandez, and

More information

Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery

Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(4):238-242 DOI: 10.3341/kjo.2011.25.4.238 Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery Original

More information

Research Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal

More information

NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS

NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS Revision Date: 6/30/06 Distribution Date: 7/6/06 The Department of Ophthalmology at the NYU Medical Center

More information

Financial Disclosures

Financial Disclosures Financial Disclosures DB is a scientific advisor for Regeneron/ Bayer and Genentech/ Roche & a DB member of the Regeneron Combination Products Steering Committee RCH receives grant support from Regeneron/

More information

Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec

Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec RUIS McGILL VIRTUAL HEALTH AND SOCIAL SERVICES CENTRE (CvSSS) SIMPLIFYING TELEHEALTH! Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec Nurse and Imager Training Prepared

More information

Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France

Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France European Journal of Ophthalmology / Vol. 17 no. 4, 2007 / pp. 521-527 Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France P.-A. KENIGSBERG PAK Santé, Paris - France PURPOSE.

More information

Role of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma

Role of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma Role of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma Mohannad Albdour MD*, Karanjit Kooner MD, PHD** ABSTRACT Objectives: To

More information

Applications of Sustained Release Delivery Systems in Ocular Disease

Applications of Sustained Release Delivery Systems in Ocular Disease Applications of Sustained Release Delivery Systems in Ocular Disease Formulation and Delivery Systems For Peptide and Protein 2012 December 5, 2012 Christopher A. Rhodes, Ph.D. Principal, Christopher A

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment

More information

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD. Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical

More information

Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review

Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review Review Ophthalmic Res 212;47:171 188 DOI: 1.1159/32963 Received: November 24, 21 Accepted after revision: May 18, 211 Published online: November 26, 211 Epidemiology of Major Eye Diseases Leading to Blindness

More information

Ophthalmology Unit Referral Guidelines

Ophthalmology Unit Referral Guidelines Ophthalmology Unit Referral Guidelines Austin Health Ophthalmology Unit holds sub-specialty sessions to discuss and plan the treatment of patients with specific ocular conditions. General including cataract

More information

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road

More information

Optometry Student Extern Manual. Miami VA Medical Center

Optometry Student Extern Manual. Miami VA Medical Center Optometry Student Extern Manual Miami VA Medical Center Table of contents: Rotation Description 3 Clinic Schedules 4 Absences 4 Performance Standards 5 When to check in with attending 5 References 6 Visual

More information

Diabetic Retinopathy Update 2017

Diabetic Retinopathy Update 2017 Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep

More information

Glaucoma. Glaucoma. Optic Disc Cupping

Glaucoma. Glaucoma. Optic Disc Cupping Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville

More information

Diabetic Retinopathy

Diabetic Retinopathy Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.

More information

Role of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria

Role of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria Original Research Article Role of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria Nkanga DG 1,2, Ibanga AA 1,2, Nkanga ED 2, Etim BA

More information

2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology

2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology 2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology Physicians must report on 50% of all patients, if reporting via registry or EHR, and 50% of all Medicare Part B patients if reporting

More information

Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage

Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage Case Report Brunei Int Med J. 2015; 11 (1): 49-53 Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage Pui Ling TANG and Mae-Lynn

More information

The Effect of Phacoemulsification with Posterior Chamber Intraocular Lens Implantation on Intraocular Pressure and Anterior Chamber Depth

The Effect of Phacoemulsification with Posterior Chamber Intraocular Lens Implantation on Intraocular Pressure and Anterior Chamber Depth The Effect of Phacoemulsification with Posterior Chamber Intraocular Lens Implantation on Intraocular Pressure and Anterior Chamber Depth Mohammad Javad Mohamadi, MD 1 Reza Soltani Moghadam, MD 1 Hasan

More information

Glaucoma Burden in a Public Sector Hospital

Glaucoma Burden in a Public Sector Hospital Original Article Glaucoma Burden in a Public Sector Hospital P.S Mahar, M Aamir Shahzad Pak J Ophthalmol 28, Vol. 24 No. 3...............................................................................

More information

DATE: 11 March 2014 CONTEXT AND POLICY ISSUES

DATE: 11 March 2014 CONTEXT AND POLICY ISSUES TITLE: Long-Term Use of Ranibizumab for the Treatment of Age-Related Macular Degeneration: A Review of the Clinical and Cost-Effectiveness and Guidelines DATE: 11 March 2014 CONTEXT AND POLICY ISSUES Age-related

More information

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Investor Update Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First Major Treatment Advance in More Than 25 Years for Sight-Threatening Condition

More information

Ophthalmology Macular Pathways

Ophthalmology Macular Pathways Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological

More information

Variability of IOP following laser photocoagulation used in the treatment of diabetic retinopathy

Variability of IOP following laser photocoagulation used in the treatment of diabetic retinopathy International Surgery Journal Agarwal S et al. Int Surg J. 2017 Oct;4(10):3433-3440 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20174511

More information

Yoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2

Yoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2 Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema

More information

Does Ranibizumab Improve Best Corrected Visual Acuity in Adults with Diabetic Macular Edema Compared to Those without Ranibizumab?

Does Ranibizumab Improve Best Corrected Visual Acuity in Adults with Diabetic Macular Edema Compared to Those without Ranibizumab? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Does Ranibizumab Improve Best Corrected

More information

Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229

Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 NICE 2018. All

More information

Optometric Cataract Refined Referral

Optometric Cataract Refined Referral Optometric Cataract Refined Referral Guidance Notes for Optometrists Version Control: v1: April 2013 v2: August 2015 REFINED CATARACT REFERRAL PATHWAY GUIDANCE FOR OPTOMETRISTS Background Approximately

More information

Growth Conference. October 19, May 2013

Growth Conference. October 19, May 2013 Dawson Corporate James Securities Presentation 3rd Annual Small Cap Growth Conference October 19, 2017 May 2013 Safe Harbor This document contains forward-looking statements within the meaning of the "safe

More information

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec

More information

Mild NPDR. Moderate NPDR. Severe NPDR

Mild NPDR. Moderate NPDR. Severe NPDR Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in

More information

Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians

Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians 16 % Injection-free after loading phase 65 % Injection-free after loading phase Navilas

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION DOI 10.1007/s40123-017-0114-6 ORIGINAL RESEARCH Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective

More information

Optic Disc Cupping: Four Year Follow-up from the WESDR

Optic Disc Cupping: Four Year Follow-up from the WESDR Investigative Ophthalmology & Visual Science, Vol. 30, o., February 989 Copyright Association for Research in Vision and Ophthalmology Optic Disc Cupping: Four Year Follow-up from the WER Barbara E. K.

More information

Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema

Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center

More information

NEPTUNE RED BANK BRICK

NEPTUNE RED BANK BRICK NEPTUNE RED BANK BRICK Diabetes & The Eye Diabetics are more likely to develop Cataracts at a younger age. Diabetics are twice as likely to develop Glaucoma when compared to non-diabetics. The primary

More information

aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer

aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Building a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. ASRS August 8, 2016

Building a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. ASRS August 8, 2016 Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. OIS @ ASRS August 8, 2016 1 Important Information Any discussion of the potential use or expected success of our product candidates

More information

OPHTHALMOLOGICAL DISORDERS

OPHTHALMOLOGICAL DISORDERS Telephone No.: 24622495 Telegraphic Address: Aeronautical: VIDDYAYX Commercial: AIRCIVIL NEW DELHI E Mail: dri@dgca.nic.in Fax:01124629211 GOVERNMENT OF INDIA AERONAUTICAL INFORMATION SERVICE DIRECTOR

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lucentis) Reference Number: CP.PHAR.186 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

CLINICAL SCIENCES. The Ocular Hypertension Treatment Study

CLINICAL SCIENCES. The Ocular Hypertension Treatment Study CLINICAL SCIENCES The Ocular Hypertension Treatment Study Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals Eve J. Higginbotham, MD; Mae O. Gordon, PhD;

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Contents METHODS... 2 Inclusion and exclusion criteria... 2 Supplementary table S1... 2 Assessment of abnormal ocular signs and symptoms... 3 Supplementary table S2... 3 Ocular

More information

Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema

Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,

More information

9/25/2017 CASE. 67 years old On 2 topical meds since 3 years. Rx: +3.0 RE LE

9/25/2017 CASE. 67 years old On 2 topical meds since 3 years. Rx: +3.0 RE LE CASE 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115 LE IOP : 17 RE 19 LE CD: 0.5 RE 0.6 LE 1 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115

More information

INTERQUAL PROCEDURES CRITERIA BIBLIOGRAPHY: OPHTHALMOLOGY

INTERQUAL PROCEDURES CRITERIA BIBLIOGRAPHY: OPHTHALMOLOGY INTERQUAL PROCEDURES CRITERIA BIBLIOGRAPHY: OPHTHALMOLOGY BIB-1 BIB-2 InterQual PROCEDURES Criteria: OPHTHALMOLOGY McKesson Clinical Evidence Classification References cited in the clinical content are

More information

VMA at the macula resulting in VMT

VMA at the macula resulting in VMT Ocriplasmina for pharmacologic treatment in VMT Teresio Avitabile 1 Introduction PVD is a normal, physiologic process that occurs with aging; however, in some cases, PVD is incomplete Incomplete PVD localized

More information